Drug Profile

NU 206

Alternative Names: NU206; R-Spondin-1; RSpo-1

Latest Information Update: 03 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kirin Pharma Company; Nuvelo
Developer Kyowa Kirin; Nuvelo; Oruka Therapeutics
Class Growth factors; Proteins
Mechanism of Action Wnt signalling pathway modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Bone disorders; Inflammatory bowel diseases; Mucositis; Rheumatoid arthritis; Stomatitis; Wounds

Most Recent Events

29 Aug 2024 ARCA biopharma Inc has merged with Oruka Therapeutics to form Oruka Therapeutics
04 Oct 2012 Discontinued - Phase-I for Bone disorders in Australia (IV)
04 Oct 2012 Discontinued - Phase-I for Mucositis in Australia (IV)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com